Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

It had also hoped to demonstrate that nasal delivery would stimulate ... testing whether its own saRNA-based shot and the AstraZeneca/Oxford vaccine can be effective when delivered by inhalation.

This application is for the study of a potential avian influenza combination therapy involving AIM's Ampligen and AstraZeneca (NASDAQ:AZN)'s FluMist, a nasal spray vaccine for seasonal influenza.

Despite financial constraints, AIM ImmunoTech Inc (AIM) progresses with promising clinical trials and strategic leadership ...

has agreed to act as the Principal Investigator for the company’s planned clinical study in the combination of Ampligen and AstraZeneca’s (AZN) FluMist as an intranasal vaccine for influenza ...

But the picture is mixed. A phase I trial of a nasal formulation of the Oxford AstraZeneca vaccine showed little to no induction of mucosal immunity and weaker systemic antibody responses compared ...

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion ... work with BioKangtai as part of a separate initiative to open a vaccine manufacturing facility in China to develop treatments for ...

In addition, AstraZeneca is launching a new joint venture with Shenzhen, Guangdong province-based BioKangtai, to develop, manufacture and commercialize innovative vaccines for respiratory and ...